SomnoMed faces a leadership shift with Co-CEO Amrita Blickstead stepping down, while preliminary FY26 revenue falls short of guidance amid European market hurdles. The launch of Virtus™, targeting patients with obstructive sleep apnea and bruxism, marks a strategic push into a niche segment.
- Co-CEO Amrita Blickstead resigns, Karen Borg becomes sole CEO
- Preliminary FY26 revenue $114-115 million below $119-126 million guidance
- EBITDA mid-range at $10-12 million supported by cost discipline
- European market challenges slow patient uptake due to reimbursement changes
- Virtus™ launches targeting OSA patients with sleep bruxism
Leadership Transition Amid Financial Shortfall
SomnoMed Limited (ASX:SOM) announced a significant executive change as Co-CEO Amrita Blickstead steps down effective 27 July 2026, leaving Karen Borg as the sole CEO. Blickstead’s six-year tenure included a transition from non-executive director to executive leadership, overseeing milestones such as treating over 1 million patients worldwide and improving manufacturing capacity and customer satisfaction. Borg praised their partnership as central to the company’s turnaround, while Blickstead expressed confidence in the company’s future under Borg’s leadership.
Preliminary FY26 Results Fall Short of Expectations
SomnoMed’s preliminary unaudited FY26 revenue came in between $114 million and $115 million, below the previously guided range of $119 million to $126 million. The shortfall is attributed to shifting market dynamics in Europe during the second half of the year and a roughly 600 basis point appreciation of the Australian dollar against key currencies. Despite this, EBITDA is estimated to be in the middle of the $10 million to $12 million guidance range, reflecting disciplined cost and capital management. The company is set to release audited results and more detailed commentary on 28 August 2026.
European Market Challenges Impact Growth
Changes to public reimbursement rules and clinical eligibility criteria in certain European markets have slowed patient access to oral appliance therapies. Additionally, shifts in referral pathways from sleep clinics to dental and community providers have affected the pace at which eligible patients receive treatment. To address this, CEO Karen Borg has spent over a month engaging directly with customers across key European regions, aiming to accelerate growth recovery. Borg’s hands-on approach mirrors her prior success driving North American growth through direct regional engagement.
FY27 Targets and Executive Promotion
Looking ahead, SomnoMed targets high single-digit revenue growth in FY27 while maintaining EBITDA margins consistent with FY26. Formal guidance will accompany the FY26 results release. The company also announced the promotion of Chief Transformation Officer Greg Knight to Chief Operating Officer, expanding his remit to include manufacturing, regulatory affairs, quality assurance, research and development, and strategy. Knight brings over 20 years of global medical device operations experience, including senior roles at Resmed.
Launch of Virtus™ Addresses Underserved Market Segment
SomnoMed has initiated a controlled market release of Virtus™, a new oral appliance designed specifically for patients with obstructive sleep apnea (OSA) who also suffer from sleep bruxism, a condition involving teeth grinding and clenching during sleep. Research published in 2023 indicates that about half of adults with OSA experience bruxism, highlighting a significant unmet clinical need. Virtus™ is engineered for enhanced strength and durability to withstand bruxism forces while maintaining comfort. Early clinician feedback underscores the commercial opportunity in this niche, potentially bolstering SomnoMed’s innovation platform and market position.
Balance Sheet and Strategic Positioning
SomnoMed enters FY27 with a robust balance sheet, holding $17.2 million in cash and a net cash position of $16.8 million. The company boasts an expanded manufacturing capability and a strengthened product pipeline, underpinned by a clear strategy to grow its share in the global oral appliance therapy market. The leadership transition, European market challenges, and new product launch collectively set the stage for a pivotal year ahead.
Bottom Line?
SomnoMed’s leadership change and FY26 revenue miss underscore near-term challenges, but the Virtus™ launch and focused European efforts could prove decisive in sustaining growth.
Questions in the middle?
- How effectively will Karen Borg’s sole leadership navigate the evolving European reimbursement landscape?
- Can Virtus™ capture meaningful market share in the niche OSA with bruxism segment?
- Will FY27 revenue growth targets hold amid ongoing currency headwinds and market shifts?